BRCA2 and prostate carcinoma: Most BRCA mutations identified in patients with prostate cancer are somatic, and, compared with low mutation levels in early prostate cancer, ∼15% of patients with metastatic androgen therapy–resistant prostate cancer harbor functionally relevant somatic mutations or deletions in BRCA1 or BRCA2 (Robinson et al. 2015).